Angina Pectoris, Angina, Stable, Angina, Unstable, Coronary Arteriosclerosis, Coronary Artery Calcification, Coronary Artery Disease, Coronary Disease, Coronary Restenosis, Stable Chronic Angina, Stent Thrombosis
Conditions
Brief summary
The purpose of the SIROOP Registry is to retrospectively and prospectively collect baseline, clinical and procedural characteristics of patients who have undergone PCI and are treated with either currently available sirolimus or paclitaxel coated DCBs (see Table 1), irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. Outcomes will be compared in different clinical subgroups. The impact of current DCBs in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.
Detailed description
Objectives in detail: * To evaluate procedural success, efficacy, performance and clinical outcomes among various patient cohorts, who undergo PCI using currently available DCBs: 1. Periprocedural outcomes/complications, which will be analyzed, include: final result (e.g. residual stenosis, TIMI flow), dissections, perforations, prevalence of thrombus (assessed by angiography and intravascular imaging) 2. Short and long-term clinical outcomes of interest comprise among others: new MI, unstable angina (UA), target lesion failure, target vessel revascularization, target lesion failure/ revascularization, repeat hospitalization, new/worsening heart failure, cardiogenic shock, stroke, bleedings, cardiovascular death and all-cause death. * To describe procedural and clinical performance of various DCB, either alone or in combination with other stent and coronary scaffold devices * To identify optimal strategies for lesion preparation in cases treated with DCB * To identify possible predictors for TLR after treatment with DCB * To describe early and late angiographic and OCT-findings among coronary artery disease (CAD) patients treated with DCB and/or various metallic stent and scaffold devices * To evaluate the impact of different antithrombotic regimens on patient's clinical outcomes * To study procedural and clinical outcomes among CAD patients requiring hemodynamic support using mechanical devices. * To describe economic implications (cost-effectiveness) of various interventional treatments for CAD.
Interventions
DEVICESirolimus Eluting Balloon
PTCA with either a Sirolimus eluting balloon or Paclitaxel eluting balloon
Sponsors
University Hospital, Geneva
Luzerner Kantonsspital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject \>18 years of age * Patients with significant acute or chronic coronary de-novo lesions or ISR lesions requiring treatment using PCI * Treatment with at least one DCB (device choice at the operator's discretion) In case of a patient with lesions treated at different procedural time, lesions will be separately collected and documented * Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).
Exclusion criteria
* Patient is \<18 years of age * Patient unwilling or unable to provide informed consent * pregnancy and lactation * Indication for surgical revascularization
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of target lesion failure (TLF) and target lesion revascularization (TLR) | at 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Rate of MACE | at 180 days, 1, 2 and 5 years |
| Rate of new MI (NSTEMI / STEMI) | at 180 days, 1, 2 and 5 years |
| Rate of TIA or stroke | at 180 days, 1, 2 and 5 years |
| Rate of acute vessel closure | at 180 days, 1, 2 and 5 years |
| Rate of stent thrombosis or ISR | at 180 days, 1, 2 and 5 years |
| Rate of target vessel revascularization (TVR) | at 180 days, 1, 2 and 5 years |
| Rate of target lesion revascularization (TLR) | at 180 days, 1, 2 and 5 years |
| Rate of target lesion failure (TLF) | at 180 days, 1, 2 and 5 years |
| Rate of ischemia driven TLR | at 180 days, 1, 2 and 5 years |
| Rate of all-cause death | at 180 days, 1, 2 and 5 years |
| Rate of cardiac death | at 180 days, 1, 2 and 5 years |
| Rate of all myocardial infarction and TV-MI | at 180 days, 1, 2 and 5 years |
| Rate of combination of major adverse cardiac and cerebrovascular events (MACCE) (including new MI, TLR or cardiovascular death) | at 180 days, 1, 2 and 5 years |
| Rate of hospitalization for HF | at 180 days, 1, 2 and 5 years |
| Rate of rehospitalization for HF, resuscitated cardiac arrest or implantable cardioverter- defibrillator (ICD) implantation | at 180 days, 1, 2 and 5 years |
| Rate of bleeding events (access site or non-access site related) according to the BARC classification | at 180 days, 1, 2 and 5 years |
| Rate of vascular complications (according to VARC criteria) | at 180 days, 1, 2 and 5 years |
| Rate of cardiogenic shock | at 180 days, 1, 2 and 5 years |
| Rate of acute renal failure/ contrast-induced nephropathy (CIN) | at 180 days, 1, 2 and 5 years |
| Rate of new ventricular arrhythmias | at 180 days, 1, 2 and 5 years |
| Rate of major adverse limb events (MALE) | at 180 days, 1, 2 and 5 years |
| Rate of new York Heart Association (NYHA) class | at 180 days, 1, 2 and 5 years |
| Rate of angina according to Canadian Cardiovascular Society (CCS) Score | at 180 days, 1, 2 and 5 years |
| Rate of procedural success (final diameter stenosis < 30% without flow-limiting dissections) | at 180 days, 1, 2 and 5 years |
| Rate of periprocedural complications (e.g. coronary perforations, no-reflow) | at 180 days, 1, 2 and 5 years |
| Rate of rehospitalization for recurrent angina | at 180 days, 1, 2 and 5 years |
Countries
Switzerland
Contacts
Primary ContactFlorim Cuculi, MD
Backup ContactMatthias Bossard, MD
Outcome results
None listed